IntroductionThe Europe Hunter Syndrome Treatment Market is experiencing significant growth driven by increased awareness of rare genetic diseases, robust research and development initiatives, and supportive regulatory frameworks. Hunter syndrome, also known as Mucopolysaccharidosis type II (MPS II), is a rare X-linked lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulfatase (I2S). The condition […]